213 related articles for article (PubMed ID: 37852183)
1. Excessive concentrations of kinase inhibitors in translational studies impede effective drug repurposing.
Liu C; Leighow SM; McIlroy K; Lu M; Dennis KA; Abello K; Brown DJ; Moore CJ; Shah A; Inam H; Rivera VM; Pritchard JR
Cell Rep Med; 2023 Oct; 4(10):101227. PubMed ID: 37852183
[TBL] [Abstract][Full Text] [Related]
2. Repurposing sertraline sensitizes non-small cell lung cancer cells to erlotinib by inducing autophagy.
Jiang X; Lu W; Shen X; Wang Q; Lv J; Liu M; Cheng F; Zhao Z; Pang X
JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875309
[TBL] [Abstract][Full Text] [Related]
3. Drug Repurposing in Non-Small Cell Lung Carcinoma: Old Solutions for New Problems.
Doumat G; Daher D; Zerdan MB; Nasra N; Bahmad HF; Recine M; Poppiti R
Curr Oncol; 2023 Jan; 30(1):704-719. PubMed ID: 36661704
[TBL] [Abstract][Full Text] [Related]
4. Development of pharmaceutically scalable inhaled anti-cancer nanotherapy - Repurposing amodiaquine for non-small cell lung cancer (NSCLC).
Parvathaneni V; Kulkarni NS; Chauhan G; Shukla SK; Elbatanony R; Patel B; Kunda NK; Muth A; Gupta V
Mater Sci Eng C Mater Biol Appl; 2020 Oct; 115():111139. PubMed ID: 32600728
[TBL] [Abstract][Full Text] [Related]
5. Guiding Drug Repositioning for Cancers Based on Drug Similarity Networks.
Qin S; Li W; Yu H; Xu M; Li C; Fu L; Sun S; He Y; Lv J; He W; Chen L
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768566
[TBL] [Abstract][Full Text] [Related]
6. Development of inhalable quinacrine loaded bovine serum albumin modified cationic nanoparticles: Repurposing quinacrine for lung cancer therapeutics.
Vaidya B; Kulkarni NS; Shukla SK; Parvathaneni V; Chauhan G; Damon JK; Sarode A; Garcia JV; Kunda N; Mitragotri S; Gupta V
Int J Pharm; 2020 Mar; 577():118995. PubMed ID: 31935471
[TBL] [Abstract][Full Text] [Related]
7. Drug repositioning in non-small cell lung cancer (NSCLC) using gene co-expression and drug-gene interaction networks analysis.
MotieGhader H; Tabrizi-Nezhadi P; Deldar Abad Paskeh M; Baradaran B; Mokhtarzadeh A; Hashemi M; Lanjanian H; Jazayeri SM; Maleki M; Khodadadi E; Nematzadeh S; Kiani F; Maghsoudloo M; Masoudi-Nejad A
Sci Rep; 2022 Jun; 12(1):9417. PubMed ID: 35676421
[TBL] [Abstract][Full Text] [Related]
8. Nanotechnology Based Repositioning of an Anti-Viral Drug for Non-Small Cell Lung Cancer (NSCLC).
Parvathaneni V; Goyal M; Kulkarni NS; Shukla SK; Gupta V
Pharm Res; 2020 Jun; 37(7):123. PubMed ID: 32514688
[TBL] [Abstract][Full Text] [Related]
9. Drug repositioning for non-small cell lung cancer by using machine learning algorithms and topological graph theory.
Huang CH; Chang PM; Hsu CW; Huang CY; Ng KL
BMC Bioinformatics; 2016 Jan; 17 Suppl 1(Suppl 1):2. PubMed ID: 26817825
[TBL] [Abstract][Full Text] [Related]
10. Repurposing old molecules for new indications: Defining pillars of success from lessons in the past.
Mittal N; Mittal R
Eur J Pharmacol; 2021 Dec; 912():174569. PubMed ID: 34653378
[TBL] [Abstract][Full Text] [Related]
11. Repositioning canakinumab for non-small cell lung cancer-important lessons for drug repurposing in oncology.
Lythgoe MP; Prasad V
Br J Cancer; 2022 Sep; 127(5):785-787. PubMed ID: 35739301
[TBL] [Abstract][Full Text] [Related]
12. Current progress and future perspectives of polypharmacology : From the view of non-small cell lung cancer.
Karuppasamy R; Veerappapillai S; Maiti S; Shin WH; Kihara D
Semin Cancer Biol; 2021 Jan; 68():84-91. PubMed ID: 31698087
[TBL] [Abstract][Full Text] [Related]
13. Drug Repurposing against KRAS Mutant G12C: A Machine Learning, Molecular Docking, and Molecular Dynamics Study.
Srisongkram T; Weerapreeyakul N
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614109
[TBL] [Abstract][Full Text] [Related]
14. Repurposing existing therapeutics, its importance in oncology drug development: Kinases as a potential target.
Islam S; Wang S; Bowden N; Martin J; Head R
Br J Clin Pharmacol; 2022 Jan; 88(1):64-74. PubMed ID: 34192364
[TBL] [Abstract][Full Text] [Related]
15. Repurposing Bedaquiline for Effective Non-Small Cell Lung Cancer (NSCLC) Therapy as Inhalable Cyclodextrin-Based Molecular Inclusion Complexes.
Parvathaneni V; Elbatanony RS; Goyal M; Chavan T; Vega N; Kolluru S; Muth A; Gupta V; Kunda NK
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946414
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models.
Fang DD; Tao R; Wang G; Li Y; Zhang K; Xu C; Zhai G; Wang Q; Wang J; Tang C; Min P; Xiong D; Chen J; Wang S; Yang D; Zhai Y
BMC Cancer; 2022 Jul; 22(1):752. PubMed ID: 35820889
[TBL] [Abstract][Full Text] [Related]
17. OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs.
Kast RE; Halatsch ME; Rosell R
Cells; 2021 May; 10(5):. PubMed ID: 34068720
[TBL] [Abstract][Full Text] [Related]
18. Drug repurposing-an emerging strategy in cancer therapeutics.
Turabi KS; Deshmukh A; Paul S; Swami D; Siddiqui S; Kumar U; Naikar S; Devarajan S; Basu S; Paul MK; Aich J
Naunyn Schmiedebergs Arch Pharmacol; 2022 Oct; 395(10):1139-1158. PubMed ID: 35695911
[TBL] [Abstract][Full Text] [Related]
19. Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer.
Morgillo F; Amendola G; Della Corte CM; Giacomelli C; Botta L; Di Maro S; Messere A; Ciaramella V; Taliani S; Marinelli L; Trincavelli ML; Martini C; Novellino E; Ciardiello F; Cosconati S
J Med Chem; 2017 Sep; 60(17):7447-7458. PubMed ID: 28787156
[TBL] [Abstract][Full Text] [Related]
20. Computational drug repurposing of Akt-1 allosteric inhibitors for non-small cell lung cancer.
Baby K; Maity S; Mehta CH; Nayak UY; Shenoy GG; Pai KSR; Harikumar KB; Nayak Y
Sci Rep; 2023 May; 13(1):7947. PubMed ID: 37193898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
